Ernexa Therapeutics Formally Executes 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing
ERNA sits 22% above its 52-week low of $3.183.
Summary
Ernexa Therapeutics Inc. filed a certificate of amendment to effect a 1-for-25 reverse stock split, effective May 4, 2026, a move aimed at regaining compliance with Nasdaq listing requirements.
Key Events · Corporate Governance and Compliance · ERNA
-
Reverse Stock Split Effective
Ernexa Therapeutics Inc. filed a certificate of amendment on May 1, 2026, to effect a 1-for-25 reverse stock split, which became effective at market open on May 4, 2026.
-
Nasdaq Compliance Measure
The reverse stock split is a critical step to help the company regain compliance with Nasdaq's minimum bid price requirement, following previous announcements regarding delisting risk.
-
New CUSIP Number Issued
Following the reverse stock split, the common stock began trading under a new CUSIP number, 114082407.
Analysis · ERNA · Life Sciences
This 8-K filing formalizes the previously announced 1-for-25 reverse stock split, which became effective at market open on May 4, 2026. The reverse split is a critical measure for Ernexa Therapeutics to regain compliance with Nasdaq's minimum bid price requirement, as the company has been at high risk of delisting and faces going concern doubts. While necessary for continued listing, this action does not address the underlying operational or financial challenges. Investors should monitor whether this compliance measure is sufficient to stabilize the company's market position and if any fundamental improvements follow.
At the time of this filing, ERNA was trading at $3.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4M. The 52-week trading range was $3.18 to $100.46. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.